Report Detail
Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Insights, Forecast to 2025
- RnM3442327 |
- 22 May, 2019 |
- Global |
- 118 Pages |
- QYResearch |
- Pharma & Healthcare
An angiotensin-converting-enzyme inhibitor (ACE inhibitor) is a pharmaceutical drug used primarily for the treatment of hypertension (elevated blood pressure) and congestive heart failure.
The global Angiotensin Converting Enzyme (ACE) Inhibitors market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Angiotensin Converting Enzyme (ACE) Inhibitors market based on company, product type, end user and key regions.
This report studies the global market size of Angiotensin Converting Enzyme (ACE) Inhibitors in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Angiotensin Converting Enzyme (ACE) Inhibitors in these regions.
This research report categorizes the global Angiotensin Converting Enzyme (ACE) Inhibitors market by top players/brands, region, type and end user. This report also studies the global Angiotensin Converting Enzyme (ACE) Inhibitors market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Abbott Laboratories
Pfizer
Novartis
Merck
Astra Zeneca
Jhonson and Johnson
Eli Lilly
Sanofi
Bristol-Myers Squibb
Bayer
GSK
Teva Pharmaceutical
Market size by Product
Sulfhydryl-containing Agents
Dicarboxylate-containing Agents
Phosphonate-containing Agents
Market size by End User
Hypertension
Cardiovascular Diseases
Kidney Diseases
Other
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Angiotensin Converting Enzyme (ACE) Inhibitors market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Angiotensin Converting Enzyme (ACE) Inhibitors market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Angiotensin Converting Enzyme (ACE) Inhibitors companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Angiotensin Converting Enzyme (ACE) Inhibitors submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Angiotensin Converting Enzyme (ACE) Inhibitors are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Angiotensin Converting Enzyme (ACE) Inhibitors market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Angiotensin Converting Enzyme (ACE) Inhibitors Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Size Growth Rate by Product
- 1.4.2 Sulfhydryl-containing Agents
- 1.4.3 Dicarboxylate-containing Agents
- 1.4.4 Phosphonate-containing Agents
- 1.5 Market by End User
- 1.5.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Size Growth Rate by End User
- 1.5.2 Hypertension
- 1.5.3 Cardiovascular Diseases
- 1.5.4 Kidney Diseases
- 1.5.5 Other
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Size
- 2.1.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue 2014-2025
- 2.1.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales 2014-2025
- 2.2 Angiotensin Converting Enzyme (ACE) Inhibitors Growth Rate by Regions
- 2.2.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Regions
- 2.2.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Manufacturers
- 3.1.1 Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Manufacturers
- 3.1.2 Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Manufacturers
- 3.1.3 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Concentration Ratio (CR5 and HHI)
- 3.2 Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Manufacturers
- 3.2.1 Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Manufacturers (2014-2019)
- 3.2.2 Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Share by Manufacturers (2014-2019)
- 3.3 Angiotensin Converting Enzyme (ACE) Inhibitors Price by Manufacturers
- 3.4 Angiotensin Converting Enzyme (ACE) Inhibitors Manufacturing Base Distribution, Product Types
- 3.4.1 Angiotensin Converting Enzyme (ACE) Inhibitors Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Angiotensin Converting Enzyme (ACE) Inhibitors Product Type
- 3.4.3 Date of International Manufacturers Enter into Angiotensin Converting Enzyme (ACE) Inhibitors Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Product
- 4.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Product
- 4.3 Angiotensin Converting Enzyme (ACE) Inhibitors Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Breakdown Data by End User
6 North America
- 6.1 North America Angiotensin Converting Enzyme (ACE) Inhibitors by Countries
- 6.1.1 North America Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Countries
- 6.1.2 North America Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Angiotensin Converting Enzyme (ACE) Inhibitors by Product
- 6.3 North America Angiotensin Converting Enzyme (ACE) Inhibitors by End User
7 Europe
- 7.1 Europe Angiotensin Converting Enzyme (ACE) Inhibitors by Countries
- 7.1.1 Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Countries
- 7.1.2 Europe Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Angiotensin Converting Enzyme (ACE) Inhibitors by Product
- 7.3 Europe Angiotensin Converting Enzyme (ACE) Inhibitors by End User
8 Asia Pacific
- 8.1 Asia Pacific Angiotensin Converting Enzyme (ACE) Inhibitors by Countries
- 8.1.1 Asia Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Countries
- 8.1.2 Asia Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Angiotensin Converting Enzyme (ACE) Inhibitors by Product
- 8.3 Asia Pacific Angiotensin Converting Enzyme (ACE) Inhibitors by End User
9 Central & South America
- 9.1 Central & South America Angiotensin Converting Enzyme (ACE) Inhibitors by Countries
- 9.1.1 Central & South America Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Countries
- 9.1.2 Central & South America Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Angiotensin Converting Enzyme (ACE) Inhibitors by Product
- 9.3 Central & South America Angiotensin Converting Enzyme (ACE) Inhibitors by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors by Countries
- 10.1.1 Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Countries
- 10.1.2 Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors by Product
- 10.3 Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors by End User
11 Company Profiles
- 11.1 Abbott Laboratories
- 11.1.1 Abbott Laboratories Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Abbott Laboratories Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Abbott Laboratories Angiotensin Converting Enzyme (ACE) Inhibitors Products Offered
- 11.1.5 Abbott Laboratories Recent Development
- 11.2 Pfizer
- 11.2.1 Pfizer Company Details
- 11.2.2 Company Business Overview
- 11.2.3 Pfizer Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 Pfizer Angiotensin Converting Enzyme (ACE) Inhibitors Products Offered
- 11.2.5 Pfizer Recent Development
- 11.3 Novartis
- 11.3.1 Novartis Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Novartis Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Novartis Angiotensin Converting Enzyme (ACE) Inhibitors Products Offered
- 11.3.5 Novartis Recent Development
- 11.4 Merck
- 11.4.1 Merck Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Merck Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Merck Angiotensin Converting Enzyme (ACE) Inhibitors Products Offered
- 11.4.5 Merck Recent Development
- 11.5 Astra Zeneca
- 11.5.1 Astra Zeneca Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Astra Zeneca Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Astra Zeneca Angiotensin Converting Enzyme (ACE) Inhibitors Products Offered
- 11.5.5 Astra Zeneca Recent Development
- 11.6 Jhonson and Johnson
- 11.6.1 Jhonson and Johnson Company Details
- 11.6.2 Company Business Overview
- 11.6.3 Jhonson and Johnson Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 Jhonson and Johnson Angiotensin Converting Enzyme (ACE) Inhibitors Products Offered
- 11.6.5 Jhonson and Johnson Recent Development
- 11.7 Eli Lilly
- 11.7.1 Eli Lilly Company Details
- 11.7.2 Company Business Overview
- 11.7.3 Eli Lilly Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 Eli Lilly Angiotensin Converting Enzyme (ACE) Inhibitors Products Offered
- 11.7.5 Eli Lilly Recent Development
- 11.8 Sanofi
- 11.8.1 Sanofi Company Details
- 11.8.2 Company Business Overview
- 11.8.3 Sanofi Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 Sanofi Angiotensin Converting Enzyme (ACE) Inhibitors Products Offered
- 11.8.5 Sanofi Recent Development
- 11.9 Bristol-Myers Squibb
- 11.9.1 Bristol-Myers Squibb Company Details
- 11.9.2 Company Business Overview
- 11.9.3 Bristol-Myers Squibb Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue and Gross Margin (2014-2019)
- 11.9.4 Bristol-Myers Squibb Angiotensin Converting Enzyme (ACE) Inhibitors Products Offered
- 11.9.5 Bristol-Myers Squibb Recent Development
- 11.10 Bayer
- 11.10.1 Bayer Company Details
- 11.10.2 Company Business Overview
- 11.10.3 Bayer Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue and Gross Margin (2014-2019)
- 11.10.4 Bayer Angiotensin Converting Enzyme (ACE) Inhibitors Products Offered
- 11.10.5 Bayer Recent Development
- 11.11 GSK
- 11.12 Teva Pharmaceutical
12 Future Forecast
- 12.1 Angiotensin Converting Enzyme (ACE) Inhibitors Market Forecast by Regions
- 12.1.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Forecast by Regions 2019-2025
- 12.1.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Forecast by Regions 2019-2025
- 12.2 Angiotensin Converting Enzyme (ACE) Inhibitors Market Forecast by Product
- 12.2.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Forecast by Product 2019-2025
- 12.2.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Forecast by Product 2019-2025
- 12.3 Angiotensin Converting Enzyme (ACE) Inhibitors Market Forecast by End User
- 12.4 North America Angiotensin Converting Enzyme (ACE) Inhibitors Forecast
- 12.5 Europe Angiotensin Converting Enzyme (ACE) Inhibitors Forecast
- 12.6 Asia Pacific Angiotensin Converting Enzyme (ACE) Inhibitors Forecast
- 12.7 Central & South America Angiotensin Converting Enzyme (ACE) Inhibitors Forecast
- 12.8 Middle East and Africa Angiotensin Converting Enzyme (ACE) Inhibitors Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Angiotensin Converting Enzyme (ACE) Inhibitors Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Angiotensin Converting Enzyme (ACE) Inhibitors. Industry analysis & Market Report on Angiotensin Converting Enzyme (ACE) Inhibitors is a syndicated market report, published as Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Angiotensin Converting Enzyme (ACE) Inhibitors market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
